Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 1,577 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO William John Sibold sold 1,577 shares of the company’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $492.42, for a total transaction of $776,546.34. Following the completion of the sale, the chief executive officer directly owned 148,497 shares of the company’s stock, valued at approximately $73,122,892.74. This trade represents a 1.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

William John Sibold also recently made the following trade(s):

• On Thursday, December 4th, William John Sibold sold 2,400 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $575.34, for a total transaction of $1,380,816.00.

Madrigal Pharmaceuticals Trading Up 3.9%

NASDAQ:MDGL opened at $499.17 on Tuesday. Madrigal Pharmaceuticals, Inc. has a one year low of $265.00 and a one year high of $615.00. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.26 and a current ratio of 3.44. The firm has a market cap of $11.34 billion, a P/E ratio of -38.37, a P/E/G ratio of 4.66 and a beta of -1.00. The firm has a 50-day simple moving average of $558.07 and a 200-day simple moving average of $461.64.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative net margin of 39.04% and a negative return on equity of 41.50%. Equities analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MDGL has been the subject of several recent research reports. Wolfe Research set a $579.00 price target on Madrigal Pharmaceuticals in a research report on Tuesday, January 6th. Truist Financial lifted their target price on Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, November 19th. HC Wainwright boosted their target price on shares of Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the stock a “buy” rating in a report on Friday, November 21st. Zacks Research cut shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 12th. Finally, Cantor Fitzgerald raised shares of Madrigal Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Madrigal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $632.64.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP boosted its stake in Madrigal Pharmaceuticals by 8.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 2,141,701 shares of the biopharmaceutical company’s stock worth $982,313,000 after purchasing an additional 165,683 shares in the last quarter. William Blair Investment Management LLC lifted its stake in shares of Madrigal Pharmaceuticals by 17.6% during the third quarter. William Blair Investment Management LLC now owns 411,802 shares of the biopharmaceutical company’s stock worth $188,877,000 after buying an additional 61,513 shares during the period. Wellington Management Group LLP lifted its stake in shares of Madrigal Pharmaceuticals by 5,381.2% during the third quarter. Wellington Management Group LLP now owns 404,455 shares of the biopharmaceutical company’s stock worth $185,507,000 after buying an additional 397,076 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in shares of Madrigal Pharmaceuticals by 96.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 376,163 shares of the biopharmaceutical company’s stock valued at $113,842,000 after buying an additional 184,554 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Madrigal Pharmaceuticals by 49.5% in the 3rd quarter. Invesco Ltd. now owns 299,565 shares of the biopharmaceutical company’s stock valued at $137,398,000 after acquiring an additional 99,209 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.